New International Start-Up Established to Support Pharmaceutical Companies in Medical Cannabis Development

November 4, 2022

International company PQE Group announced in late October their first ever start-up to provide support for medical cannabis.

PQE Group, an international life sciences consulting company, announced the establishment of the world’s first start-up to support pharmaceutical companies in medical cannabis development in a recent press release (1). The start-up, called Glocal Quality Cannabis (GQC) will reportedly provide services including engineering, GxP quality compliance, regulatory affairs, medical-scientific advisory, clinical studies, and a GQC academy. According to their website (2), “PQE Group is a woman-owned, ISO 9001-certified technology solutions and compliance consulting services company for the life sciences industry, providing global capabilities deliverable throughout the entire product quality life cycle.”

In their press release (1), Gilda D'Incerti, PQE Group CEO and Founder and President of GQC, explained that this project represents an important challenge for her, adding that she strongly believes in the therapeutical power of cannabis. “I wanted to support the field of research as well as the development and dissemination of medical cannabis through the creation of this new start-up,” said D'Incerti. “I personally, and with great care, researched the professionals who make up the new GQC team: chemists, pharmacists, physicians, and biologists who take care of the supply chain at three hundred and sixty degrees.”

QGC will address the market’s struggles with fragmented legislation by applying “the highest international standards locally to always guarantee efficacy, safety, and quality to the end patient” (1).

"I believe that medical cannabis should be treated the same as any other pharmaceutical product,” Riccardo Salvagnini, GQC VP Executive, said during the start-up's launch ceremony (1). “Our vision is to support the development of new therapies through effective management of data quality by accelerating the registration of cannabis products and reducing the timing of the supply chain to be faster for the patients. Therefore, we want to provide effective technological solutions to medical cannabis products to accelerate our go-to-market strategy through a local approach but with a global mindset.”

References